Vertex Reports long-term follow-up Data for Alirocumab in Hemophilia A

Vertex today announced long-term follow-up results for alirocumab in patients with hemophilia A. The study demonstrated that alirocumab reduces adverse events compared to standard of care or placebo. These results provide important insights into the treatment of hemophilia A and support the continued development of alirocumab in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.